{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06320366",
            "orgStudyIdInfo": {
                "id": "23-1044"
            },
            "secondaryIdInfos": [
                {
                    "id": "K24DA058882",
                    "type": "NIH",
                    "link": "https://reporter.nih.gov/quickSearch/K24DA058882"
                }
            ],
            "organization": {
                "fullName": "University of Colorado, Denver",
                "class": "OTHER"
            },
            "briefTitle": "Testing an Accelerated TMS Protocol for Methamphetamine Use Disorder",
            "officialTitle": "Testing an Accelerated TMS Protocol for Methamphetamine Use Disorder",
            "therapeuticArea": [
                "Other"
            ],
            "study": "testing-an-accelerated-tms-protocol-for-methamphetamine-use-disorder"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-06",
            "overallStatus": "NOT_YET_RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-07-01",
                "type": "ESTIMATED"
            },
            "primaryCompletionDateStruct": {
                "date": "2028-05-31",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2028-05-31",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-03-13",
            "studyFirstSubmitQcDate": "2024-03-13",
            "studyFirstPostDateStruct": {
                "date": "2024-03-20",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-06-07",
            "lastUpdatePostDateStruct": {
                "date": "2024-06-10",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "University of Colorado, Denver",
                "class": "OTHER"
            },
            "collaborators": [
                {
                    "name": "National Institute on Drug Abuse (NIDA)",
                    "class": "NIH"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": false,
            "isFdaRegulatedDevice": true,
            "isUsExport": false
        },
        "descriptionModule": {
            "briefSummary": "The investigators will evaluate the effects of an accelerated Transcranial Magnetic Stimulation (TMS) protocol of the left dorsolateral prefrontal cortex (DLPFC) for moderate to severe methamphetamine use disorder. This is a randomized parallel group design to assess feasibility and safety, evaluate efficacy (use, craving) and identify magnetic resonance imaging (resting state and cue craving) associated with group/outcomes.",
            "detailedDescription": "In a randomized double-blind parallel-group sham-controlled design (n=20) administer a 5-day accelerated iTBS protocol (40 treatments) to the left dorsolateral prefrontal cortex during a short inpatient stay. Magnetic resonance imaging will be completed pre-post TMS and participants will be followed for 12 weeks."
        },
        "conditionsModule": {
            "conditions": [
                "Methamphetamine Use Disorder"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "NA"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "interventionModelDescription": "Sham vs. real Transcranial Magnetic Stimulation (TMS)",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "TRIPLE",
                    "maskingDescription": "Participant and all study personnel are blinded.",
                    "whoMasked": [
                        "PARTICIPANT",
                        "INVESTIGATOR",
                        "OUTCOMES_ASSESSOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 20,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Sham TMS",
                    "type": "PLACEBO_COMPARATOR",
                    "description": "Participants have baseline assessments/evaluation, are admitted to the inpatient research unit, randomized via permuted block design to 5 days of sham TMS, and then have weekly study visits for the next 12 weeks.",
                    "interventionNames": [
                        "Device: Sham TMS"
                    ]
                },
                {
                    "label": "Active TMS",
                    "type": "EXPERIMENTAL",
                    "description": "Participants have baseline assessments/evaluation, are admitted to the inpatient research unit, randomized via permuted block design to 5 days of active TMS, and then have weekly study visits for the next 12 weeks.",
                    "interventionNames": [
                        "Device: Active TMS"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DEVICE",
                    "name": "Sham TMS",
                    "description": "The TMS Cool-B65 A/P coil on its placebo side delivers electrical stimulation to the scalp (e.g., mimicking sensations associated with real stimulation) but does not provide magnetic stimulation to the targeted cortical structure.",
                    "armGroupLabels": [
                        "Sham TMS"
                    ]
                },
                {
                    "type": "DEVICE",
                    "name": "Active TMS",
                    "description": "The TMS Cool-B65 A/P coil delivers magnetic stimulation to targeted cortical structure.",
                    "armGroupLabels": [
                        "Active TMS"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Tolerability",
                    "description": "Proportion completing at least 20 TMS session - sham vs. active",
                    "timeFrame": "5 days"
                },
                {
                    "measure": "Study emergent adverse events",
                    "description": "Incidence of study emergent adverse events - sham vs. active",
                    "timeFrame": "12 weeks"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Weeks of continuous abstinence",
                    "description": "Number of weeks of continuous methamphetamine abstinence - sham vs. active as measured weekly by urine drug screen.",
                    "timeFrame": "12 weeks"
                },
                {
                    "measure": "Days of methamphetamine use",
                    "description": "Number of days of methamphetamine use - sham vs. active as measured weekly by timeline followback interview.",
                    "timeFrame": "12 weeks"
                },
                {
                    "measure": "Methamphetamine craving",
                    "description": "Craving as measured on the Stimulant Craving Questionnaire-Brief - sham vs. active. Each item is scored 0-6 (from Strongly Disagree=0 to Strongly Agree=6) with items #4 and #7 reverse scored. The investigators will average all 10 items as the total score, with higher scores indicating greater levels of craving.",
                    "timeFrame": "12 weeks"
                },
                {
                    "measure": "Methamphetamine craving on visual analog scale",
                    "description": "Craving as measured on visual analog scale - sham vs. active. Scored 0 to 100 with 0=no craving and 100=the most craving.",
                    "timeFrame": "12 weeks"
                },
                {
                    "measure": "MRI cue craving",
                    "description": "Cue craving data will be collected pre- and post-TMS stimulation in week 1",
                    "timeFrame": "Pre- and Post- TMS stimulation in week 1"
                },
                {
                    "measure": "MRI resting state",
                    "description": "Resting state data will be collected pre- and post-TMS stimulation in week 1",
                    "timeFrame": "Pre- and Post- TMS stimulation in week 1"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n1. Age 21-65 years inclusive;\n2. Meets DSM-5 criteria for past-year moderate or severe methamphetamine use disorder;\n3. By Timeline Follow Back endorses at least 10 days of methamphetamine use out of the last month;\n4. Provides a urine drug screen positive for methamphetamine;\n5. Able to provide informed consent;\n6. No change in current psychiatric medication regimen, or medication free, for at least 4 weeks prior to study entry;\n7. Adequate English proficiency for study consent, and completion of the study instruments.\n\nExclusion Criteria:\n\n1. Lifetime non-substance-induced psychotic disorders, schizophrenia, schizoaffective disorder or bipolar disorder defined by DSM-5;\n2. Current diagnosis of DSM-5 drug use disorder other than stimulant, cannabis or nicotine use disorder;\n3. Non-substance-induced manic episode within the past 3 years or major depressive episode in the past year;\n4. Current clinically significant neurological disorder or medical illness, including history of seizures, cardiovascular disease/cardiac event, which in the opinion of the study physician would make study participation unsafe;\n5. Presence of a clinically significant abnormality on baseline MRI;\n6. Inability to have an MRI;\n7. Currently breastfeeding, is currently pregnant or lack of use of effective contraception in women of childbearing age, as assessed by urine pregnancy test and self-report (participants will consent to continue effective contraceptives during the study);\n8. Active criminal justice involvement (i.e., any unresolved legal problems that could jeopardize continuation or completion of the study);\n9. History of head injury with loss of consciousness for more than 15 minutes;\n10. Diagnosis of dementia;\n11. Prescribed benzodiazepines or anticonvulsants;\n12. Currently enrolled in formal substance use disorder treatment;\n13. Metal implants or non-removable metal objects above the waist;\n14. Lifetime history of prior clinical treatment with TMS;\n15. Serious risk of suicide or homicide;\n16. Unable/unwilling to follow the study procedures;\n17. History of intractable migraine;\n18. Assessed to be at risk for alcohol or opioid withdrawal.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "21 Years",
            "maximumAge": "65 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Joseph T Sakai, MD",
                    "role": "CONTACT",
                    "phone": "303-724-7402",
                    "email": "joseph.sakai@cuanschtz.edu"
                },
                {
                    "name": "Kristen M Raymond, BA",
                    "role": "CONTACT",
                    "phone": "303-724-3196",
                    "email": "kristen.raymond@cuanschutz.edu"
                }
            ],
            "locations": [
                {
                    "facility": "University of Colorado Anschutz Medical Campus",
                    "city": "Aurora",
                    "state": "Colorado",
                    "zip": "80045",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Joseph T Sakai, MD",
                            "role": "CONTACT",
                            "phone": "303-724-7402",
                            "email": "joseph.sakai@cuanschutz.edu"
                        },
                        {
                            "name": "Kristen M Raymond, BA",
                            "role": "CONTACT",
                            "phone": "303-724-3196",
                            "email": "kristen.raymond@cuanschutz.edu"
                        },
                        {
                            "name": "Joseph T Sakai, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 39.72943,
                        "lon": -104.83192
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO",
            "description": "No plan to share IPD."
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "interventionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M11674",
                    "name": "Methamphetamine",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "CNSSti",
                    "name": "Central Nervous System Stimulants"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}